Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Details : IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with RAS-mutant melanoma.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 12, 2024
Lead Product(s) : IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?